Targeting epigenetics as atherosclerosis treatment: an updated view

This review discusses the current developments on epigenetic inhibition as treatment for atherosclerosis. RECENT FINDINGS: The first phase III clinical trial targeting epigenetics in cardiovascular disease (CVD), BETonMACE, using the bromodomain inhibitor apabetalone (RVX-208) showed no significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Neele, Annette E., Willemsen, Lisa, Chen, Hung-Jen, Dzobo, Kim E., de Winther, Menno P.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752220/
https://www.ncbi.nlm.nih.gov/pubmed/33027226
http://dx.doi.org/10.1097/MOL.0000000000000711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752220/
https://www.ncbi.nlm.nih.gov/pubmed/33027226
http://dx.doi.org/10.1097/MOL.0000000000000711

Ejemplares similares